(83 days)
The Duploject® is intended for use in the simultaneous delivery of two non-homogenous fluids or solutions onto a surgical site. The Duploject® is equipped with a syringe holder, which assures controlled, accurate dispensing, and a needle holder, which allows the contents of the syringes to mix prior to dispensing.
The Duploject® is a single-use, disposable syringe, which is used in the application of two nonhomogenous fluids or solutions onto a surgical site. The Duploject® consists of two disposable syringes and withdrawal needles for reconstitution of the solutions. It also contains the following components for use in the simultaneous application of the two solutions: a clip, with a common plunger, is used to join the two identical disposable syringes together and ensures that equal volumes of the two components are fed through a common joining piece and mixed prior to dispensing. Three extra application needles and one extra joining piece are included in the package to use as replacements, if needed. The Duploject® is sterile and non-pyrogenic.
This looks like a 510(k) premarket notification for a medical device called Duploject®. However, it does not contain the specific information you requested regarding acceptance criteria or the study proving the device meets those criteria.
The provided text focuses on:
- Device Description: What the Duploject® is and how it works.
- Intended Use: The purpose of the device.
- Comparison to Predicate Devices: How the Duploject® is similar to other legally marketed devices (Duoflo Dispenser, RMI Dual Fluid Irrigating Syringe, Surgical Sealant Dispenser). This comparison table is a key part of establishing substantial equivalence, which is the basis for 510(k) clearance.
- FDA Clearance Letter: Official communication from the FDA stating that the device is substantially equivalent and can be marketed.
While the table labeled "Comparison of device characteristics to predicate" does list "Delivery Accuracy," it only states "The slide bar on the syringe holder ensures delivery of equal amounts of the contents of the syringes." This is a feature description, not a quantitative acceptance criterion or a report of measured performance. There is no study data presented to "prove" this beyond the assertion.
Therefore, I cannot provide the requested information from the given text alone. The document is a regulatory submission for substantial equivalence based on comparison to predicate devices, not a detailed performance study report.
{0}------------------------------------------------
K9 73510
DEC - 8 1997
510(k) Summary of Safety and Effectiveness Duploject®
Submitter
Immuno- US, Inc. Ron Vallencourt, DVM Vice President Regulatory Affairs 1200 Parkdale Road Rochester, Michigan Tel: 248-608-3202 Fax: 248-652-0670
Date summary was prepared
Spetember 16, 1997
Name(s) of the device
Duploject®
Identification of predicate device(s)
Duoflo Dispenser K872565 Manufactured by Hemaedics, Inc.
RMI Dual Fluid Irrigating Syringe K964833 Manufactured by Research Medical, Inc.
Surgical Sealant Dispenser (SSD) K881020 Micromedics, Inc.
Description of the device
The Duploject® is a single-use, disposable syringe, which is used in the application of two nonhomogenous fluids or solutions onto a surgical site. The Duploject® consists of two disposable syringes and withdrawal needles for reconstitution of the solutions. It also contains the following components for use in the simultaneous application of the two solutions: a clip, with a common plunger, is used to join the two identical disposable syringes together and ensures that equal volumes of the two components are fed through a common joining piece and mixed prior to dispensing. Three extra application needles and one extra joining piece are included in the package to use as replacements, if needed. The Duploject® is sterile and non-pyrogenic.
{1}------------------------------------------------
Intended Use
The Duploject® is intended for use in the simultaneous delivery of two non-homogenous fluids or solutions onto a surgical site. The Duploject® is equipped with syringe holder, which assures controlled, accurate dispensing, and a needle holder, which allows the contents of the syringes to mix prior to dispensing.
| Characteristic | Duploject® | Predicate Devices |
|---|---|---|
| Principle ofOperation | A joining piece, with a commonplunger, connects two disposablesyringes, and the contents are mixed ina common tip prior to dispensing. | Same |
| Volume | 0.5/1.0 ml, 2 ml,5 ml | Same |
| DeliveryAccuracy | The slide bar on the syringe holderensures delivery of equal amounts ofthe contents of the syringes. | Same |
| Reuse | Disposable | Same |
| Sterilization | EtO (106) | Same |
Comparison of device characteristics to predicate
Conclusion
The intended use, design, materials of fabrication, and performance of the Duploject® are the predicate devices. Therefore, the Duploject® is substantially equivalent to piston syringes marketed in interstate commerce prior to May 28,1 976.
{2}------------------------------------------------
Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. In the center of the logo is an abstract symbol that resembles a stylized human figure or a bird in flight.
DEC - 8 1997
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
David West, Ph.D. Senior Technical Advisor Immuno-U.S., Incorporated C/O Medical Technology Consultants 15825 Shady Grove Road, Suite 90 Rockville, Maryland 20850
Re : K973510 Duploject (0.5/1.0 ML, 5.0 ML) Trade Name: Regulatory Class: II Product Code: FMF Dated: September 16, 1997 Received: September 16, 1997
Dear Dr. West:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. ਸ substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Requlation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531
{3}------------------------------------------------
Page 2 - Dr. West
through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Tim Directbr Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
INDICATIONS FOR USE 5.0
The Duploject® is intended for use in the simultaneous delivery of two non-homogenous fluids or solutions onto a surgical site. The Duploject® is equipped with a syringe holder, which assures controlled, accurate dispensing, and a needle holder, which allows the contents of the syringes to mix prior to dispensing.
Patrici Cuscenti
510k)
Prescription Use. ✓
(Per 21 CFR 801.109)
September 17, 1997 Immuno-Duploject®
§ 880.5860 Piston syringe.
(a)
Identification. A piston syringe is a device intended for medical purposes that consists of a calibrated hollow barrel and a movable plunger. At one end of the barrel there is a male connector (nozzle) for fitting the female connector (hub) of a hypodermic single lumen needle. The device is used to inject fluids into, or withdraw fluids from, the body.(b)
Classification. Class II (performance standards).